Oncology · PROTAC protein degrader (oral, once daily)

Vepdegestrant (Veppanu)

Vepdegestrant (Veppanu) is an oral protein degrader approved by the FDA in May 2026 for ER-positive, HER2-negative breast cancer with an ESR1 mutation. It is the first approved drug of the PROTAC class.

FDA-approvedFDA-approved May 1, 2026 for ESR1-mutated breast cancer: the first approved PROTAC

FDA-approved: Approved by the FDA for at least one use. Other uses may still be in clinical trials. About status badges

FDA: approved as VEPPANU (NDA219835), original approval May 1, 2026. Approval covers specific uses only; see programs below.

DeveloperArvinas (partners: Pfizer)
Drug typePROTAC protein degrader (oral, once daily)
TargetEstrogen receptor (ER)
MechanismTags the estrogen receptor for destruction by the cell's own protein-disposal system, rather than just blocking it
Other namesARV-471, PF-07850327

Key points

  • Vepdegestrant is a PROTAC: a molecule that recruits the cell's protein-disposal machinery to destroy the estrogen receptor.
  • In the 624-patient VERITAC-2 trial, it extended median progression-free survival in patients with ESR1 mutations: 5.0 months versus 2.1 months with fulvestrant.
  • In the full trial population, the difference was not statistically significant (3.8 vs 3.6 months; p = 0.07), so approval is limited to ESR1-mutated cancer.
  • The FDA approved it on May 1, 2026, alongside a companion diagnostic (Guardant360 CDx) to identify eligible patients.
  • Arvinas and Pfizer said they planned to select a third party to commercialize it (company-reported).

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
ER-positive, HER2-negative breast cancer
Approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy (FDA). VERITAC-3 is listed as active (registry).
Approved (FDA, May 1, 2026) for ESR1-mutated disease13
6 active · 4 completed · 2 stopped
Not shown (see note)

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What vepdegestrant is

Most breast cancers are driven by the estrogen receptor (ER). Standard hormone therapies either lower estrogen or block the receptor. Vepdegestrant, developed by Arvinas with Pfizer, works differently. It is a PROTAC (proteolysis-targeting chimera), a two-ended molecule that grabs the estrogen receptor with one end and a cellular "tagging" enzyme with the other. The tagged receptor is then destroyed by the cell's own protein-disposal system.

According to Arvinas, it is the first PROTAC to be approved by the FDA, a milestone for the wider field of targeted protein degradation.

Why the ESR1 mutation matters

After months of hormone therapy, many breast cancers develop mutations in ESR1, the gene for the estrogen receptor. These mutations can keep the receptor switched on even without estrogen, making older treatments less effective. A drug that destroys the receptor outright is designed to overcome this. That is also why a blood test for ESR1 mutations, a companion diagnostic, decides who is eligible. See What Is Precision Medicine?

Clinical evidence: VERITAC-2

VERITAC-2 randomized 624 patients whose ER-positive, HER2-negative advanced breast cancer had progressed after earlier therapy, comparing vepdegestrant with fulvestrant, an injected hormone therapy.

Population Vepdegestrant (median PFS) Fulvestrant (median PFS) Hazard ratio
ESR1-mutated (270 patients) 5.0 months 2.1 months 0.58 (NEJM); 0.57 (FDA)
All patients 3.8 months 3.6 months 0.83 (p = 0.07, not significant)

Sources: Campone et al., NEJM (2025); FDA approval announcement. The two hazard ratios for the ESR1 group come from analyses reported separately by the investigators and the FDA.

Grade 3 or higher adverse events occurred in 23.4% of patients on vepdegestrant and 17.6% on fulvestrant, and treatment was stopped because of adverse events in 2.9% and 0.7%, respectively.

Regulatory status

The FDA approved Veppanu (vepdegestrant) on May 1, 2026, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx blood test as its companion diagnostic. The recommended dose is 200 mg once daily with food, and the FDA acted one month ahead of its goal date.

Scientific perspective

VERITAC-2 shows why approvals in oncology increasingly target biomarker-defined populations. In the full trial the benefit was small and not statistically significant. In patients with ESR1 mutations, the group the drug's mechanism is designed for, the benefit was clear. The label follows the evidence: approval covers the ESR1-mutated group only.

Development perspective

  • Approved use: ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy. No benchmark is shown for an approved program.
  • Commercialization: Arvinas and Pfizer said they planned to select a third party to commercialize Veppanu (company-reported).
  • Class significance: success here supports the broader PROTAC and protein-degradation approach, which many companies are applying to other targets.

Development timeline

  1. Jan 31, 2025VERITAC-2 Phase 3 trial reaches primary completion. Registry
  2. May 31, 2025VERITAC-2 published: progression-free survival 5.0 vs 2.1 months in ESR1-mutated patients; not significant in the overall population. Peer-reviewed
  3. May 1, 2026FDA approves Veppanu (vepdegestrant) with the Guardant360 CDx companion diagnostic, one month ahead of its goal date. Regulator

What could change the outlook

  • Commercial launch arrangements, including the third-party partner Arvinas and Pfizer said they would select (company-reported).
  • Competition from other oral estrogen receptor degraders approved for ESR1-mutated breast cancer.
  • Whether the PROTAC approach succeeds against other targets, which would make vepdegestrant the first of a broader class.
  • VERITAC-3 and other combination studies listed in the registry.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Vepdegestrant. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedNov 3, 2026

    Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    External expenses include (i) program-specific expenses, which decreased by $6.7 million, primarily driven by a decrease in the vepdegestrant (ARV-471) program of $14.2 million, partially offset by increases in the ARV-027, ARV-6723, and ARV-393 programs of $4.6 million, $3.3 million, and $3.2 million...

    Company
    Arvinas, Inc.
    Source
    SEC Form 8-K · Financial results, Regulation FD disclosure
  2. Quarterly reportCompany-reportedNov 3, 2026

    IGNITING A TRANSFORMATIVE CHANGE in the fight for patients with cancer and neurodegenerative diseases

    PROTAC:, proteolysis targeting chimera a. vepdegestrant, bavdegalutamide, luxdegalutamide (JSB462), ARV-102, ARV-393, ARV-806, ARV-027, ARV-6723 Our experienced and talented team is advancing a new therapeutic modality for patients 4 History of FIRSTS with our novel Clinical trials in oncology Discovery Clinical...

    Company
    Arvinas, Inc.
    Source
    SEC Form 8-K · Financial results, Regulation FD disclosure
  3. RegulatoryCompany-reportedAug 13, 2026

    Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU TM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth...

    Company
    Rigel Pharmaceuticals, Inc.

All Vepdegestrant disclosures in Pipeline News

Clinical trials

24 registered trials list Vepdegestrant as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

ER-positive, HER2-negative breast cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
VERITAC-2 · NCT05654623
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Phase 3Active, not recruiting624Jan 31, 2025Yes
VERITAC-3 · NCT05909397
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Phase 3Active, not recruiting59Dec 30, 2026 (est.)No
I-SPY · NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2Recruiting5,000 (est.)Dec 2030 (est.)No
KAT6 · NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Phase 2Recruiting320 (est.)Aug 27, 2029 (est.)No
mBC · NCT04072952
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Phase 1/2Completed219Sep 13, 2024Yes
NCT05549505
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Phase 2Completed152Jul 13, 2024Yes
NCT06206837
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Phase 1/2Active, not recruiting71Sep 5, 2025Yes
NCT05548127
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Phase 1/2Active, not recruiting37Mar 24, 2027 (est.)No
NCT05573555
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Why stopped (registry): Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.
Phase 1/2Terminated20Oct 6, 2026No
NCT06125522
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Why stopped (registry): Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
Phase 1/2Terminated11Sep 10, 2026No
3 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
TACTIVE-E · NCT05501769
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
Phase 1Completed32Jul 3, 2024No
NCT05732428
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China
Phase 1Completed9Mar 29, 2024No
NCT05463952
A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
Phase 1Unknown status6May 4, 2023Yes

Clinical pharmacology and supporting studies

11 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06347861
A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults
Phase 1Completed52Jul 22, 2024No
NCT05673889
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
Phase 1Completed24Mar 15, 2023Yes
NCT07231991
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Phase 1Recruiting24 (est.)Dec 4, 2026 (est.)No
NCT06256510
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam
Phase 1Completed15Apr 16, 2024No
NCT05538312
A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults
Phase 1Completed12Apr 24, 2023Yes
NCT05652660
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
Phase 1Completed12Feb 9, 2023Yes
NCT05930925
A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults
Phase 1Completed12Jul 27, 2023No
PK · NCT06005688
A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants
Phase 1Completed12Oct 11, 2023No
NCT06275841
A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant
Phase 1Completed12May 3, 2024No
NCT06645938
A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults
Phase 1Completed12Feb 20, 2025No
NCT06911788
A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults
Phase 1Completed10May 23, 2025No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (May 1, 2026).Regulator
  2. Campone M, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer (VERITAC-2). New England Journal of Medicine. 2025;393(6):556–568.Peer-reviewed
  3. Arvinas. Form 8-K exhibit: FDA approval of Veppanu (May 2026).Company-reported
  4. ClinicalTrials.gov. VERITAC-2 (NCT05654623).Registry
  5. U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices.Regulator
  6. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.